Figure 3.

Transgenic death receptor 5 (DR5) expression on CD4 T cells and TRA-8–induced depletion of IL-17⁺ IFN-γ⁺ and granulocyte-macrophage colony-stimulating factor-positive (GM-CSF⁺) inflammatory CD4 T cells in DR5-transgenic B6-me^v/me^v mice. A. Top panels, Percentage of Th1 (CD4⁺, IFN-γ⁺, IL-17A⁻), Th1/17 (CD4⁺, IFN-γ⁺, IL-17A⁺), and Th17 (CD4⁺, IFN-γ⁻, IL-17A⁺) T cells in the spleen of B6-+/+ and B6-me^v/me^v mice with and without transgenic DR5, as determined by FACS analysis. Bottom panels, Expression of transgenic DR5 on CD4 T cells that were divided into 4 subpopulations based on their expression of IFN-γ and IL-17A. B, Top, Percentage of GM-CSF⁺ and GM-CSF⁻ CD4 T cells from the spleen of DR5-transgenic B6-me^v/me^v mice. Bottom, Expression of transgenic DR5 on cells in each subset. C, Effect of TRA-8 and isotype control treatment on the percentage of Th1, Th1/17, Th17, and GM-CSF+ CD4 T cells in spleen of DR5-transgenic B6-me^v/me^v mice. D. Total number of each subset of CD4 T cells after treatment with isotype control or TRA-8 was determined by multiplying the total cell count by the percentage of each indicated CD4 T cell subpopulation. Values are the mean ± SEM (n = 5 mice per group). *** = P < 0.001. NA = not applicable (see Figure 1 for other definitions).